Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Insider Trading Activity
View recent insider purchases and sales for Maze Therapeutics, Inc. (MAZE), including transaction dates, insiders, share amounts, prices, and transaction values. Only open-market buys and sales are shown, grouped per insider per day.
★ ZCoreAI PREMIUM7 days free
Start Your 7-Day MAZE Premium Trial
Explore the complete MAZE setup with live Z-Score, Smart Money signals, multi-timeframe analysis and premium indicators.
✓Z-Score signals
✓Smart Money flow
✓All timeframes
✓Premium indicators
Start 7-Day Free Trial →
7-day free trial. No commitment during the trial.
Last 12 months of reported activity
Insider buys
0
Insider sells
13
Value sold
$5.51M
Net activity
−$5.51M
Buying vs selling by month
Transaction value per month, buys above and sales below.
26-08
26-09
26-10
26-11
Recent insider transactions
13 reported trades, most recent first.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Coloma Jason V | Sell | 34,501 | $30.25 | $1.04M |
| Oct 29, 2026 | Dandekar Atul | Sell | 7,500 | $32.07 | $241K |
| Oct 1, 2026 | Coloma Jason V | Sell | 34,501 | $27.02 | $932K |
| Oct 1, 2026 | Bernstein Harold | Sell | 16,141 | $26.93 | $435K |
| Sep 29, 2026 | Dandekar Atul | Sell | 7,500 | $27.06 | $203K |
| Sep 4, 2026 | Bernstein Harold | Sell | 9,705 | $26.22 | $255K |
| Sep 3, 2026 | Coloma Jason V | Sell | 11,411 | $26.01 | $297K |
| Sep 3, 2026 | Bernstein Harold | Sell | 5,189 | $26.01 | $135K |
| Sep 2, 2026 | Coloma Jason V | Sell | 11,227 | $26.47 | $297K |
| Sep 2, 2026 | Bernstein Harold | Sell | 5,106 | $26.47 | $135K |
| Sep 1, 2026 | Coloma Jason V | Sell | 34,501 | $26.29 | $907K |
| Sep 1, 2026 | Bernstein Harold | Sell | 16,141 | $26.36 | $426K |
| Aug 28, 2026 | Dandekar Atul | Sell | 7,500 | $27.58 | $207K |
MAZE overview
Live chart, fundamentals and valuation context.
MAZE earnings
Quarterly EPS and revenue results.
See insiders on the chart
Analyze MAZE in the ZCoreAI Terminal →
Based on reported insider filings. Informational only — not investment advice.